EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France

Francois Schiele, Michel Farnier, Bénédicte Borsik

Archives of Cardiovascular Diseases · 2025

DOI: 10.1016/j.acvd.2025.08.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Cardiovascular Diseases, 2025. Verfasst von Francois Schiele und 2 weiteren Autor:innen. Beteiligte Einrichtung: Regional University Hospital Jean-Minjoz, 3, boulevard Alexandre-Fleming, 25030 Besançon, France. Electronic address: francois.schiele@univ-fcomte.fr. Hauptthemen laut MEDLINE: Cholesterol, LDL, Ezetimibe, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dicarboxylic Acids. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi Sankyo Europe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lipid-lowering therapies effectively reduce low-density lipoprotein cholesterol concentrations and the risk of cardiovascular events, but barriers such as statin intolerance, non-adherence and discontinuation can leave patients at risk. AIM: This study characterized statin-intolerant patients in France, and modelled the low-density lipoprotein cholesterol-lowering effects of ezetimibe and bempedoic acid for those at elevated cardiovascular risk. METHODS: Patients were identified based on IQVIA electronic medical records from 1200 general practitioners (September 2022 to August 2023), and this sample was extrapolated to represent the French population. Patients were identified as at high or very high probability of statin intolerance based on statin-associated muscle symptoms, statin downtitration or intermittent dosing/statin switch. The low-density lipoprotein cholesterol-lowering effect of stepwise addition of ezetimibe and bempedoic acid was modelled using a Monte Carlo simulation. RESULTS: Among patients at high or very high cardiovascular risk, 478,370 had statin intolerance: 54.5% at high and 45.5% at very high probability. Overall, 3.6% of patients were not receiving lipid-lowering therapy; most were receiving monotherapy with statins (46.8%) or ezetimibe (24.6%), and 24.4% were receiving a statin+ezetimibe. Of 179,458 patients with a low-density lipoprotein cholesterol result within 12 months and who received lipid-lowering therapy within 3.5 months of the index date, 90% (n=160,633) were not at low-density lipoprotein cholesterol goal at simulation baseline. In this population, adding ezetimibe reduced the mean low-density lipoprotein cholesterol concentration from 127 to 112mg/dL, with a 10.7% increase in goal attainment. Adding bempedoic acid in patients not at goal after ezetimibe further decreased the low-density lipoprotein cholesterol concentration to 86mg/dL, increasing goal attainment to 39.1%. CONCLUSIONS: Most (90%) statin-intolerant patients in France do not meet low-density lipoprotein cholesterol goals, emphasizing the need for therapeutic strategies and evidence-based guidelines to improve outcomes. This simulation suggests that treatment escalation could increase low-density lipoprotein cholesterol goal attainment to ∼11% with ezetimibe, and to ∼40% with ezetimibe+bempedoic acid.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsDicarboxylic AcidsAnticholesteremic AgentsDyslipidemiasCardiovascular DiseasesHumansFranceMaleFemaleMiddle AgedAgedTreatment OutcomeBiomarkersAdministration, OralTime FactorsComputer SimulationRisk AssessmentDrug Therapy, CombinationDrug ToleranceRetrospective StudiesHeart Disease Risk FactorsFatty Acids

Stichwörter der Autor:innen

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidCardiovascular diseasesEzetimibeHydroxymethylglutaryl-CoA reductase inhibitorsLipoproteins

Substanzen

Cholesterol, LDLEzetimibeHydroxymethylglutaryl-CoA Reductase Inhibitors8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidDicarboxylic AcidsAnticholesteremic AgentsBiomarkersFatty Acids

Autor:innen und Institutionen

  • Regional University Hospital Jean-Minjoz, 3, boulevard Alexandre-Fleming, 25030 Besançon, France. Electronic address: francois.schiele@univ-fcomte.fr.
  • PEC2 UR 7460, université de Bourgogne Europe, 21000 Dijon, France.
  • IQVIA, 33800 Bordeaux, France.

Förderung

  • Daiichi Sankyo Europe

Zitieren

APA

Schiele, F., Farnier, M., & Borsik, B. (2025). Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France. Archives of Cardiovascular Diseases. https://doi.org/10.1016/j.acvd.2025.08.008

Vancouver

Schiele F, Farnier M, Borsik B. Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France. Archives of Cardiovascular Diseases. 2025. doi:10.1016/j.acvd.2025.08.008

BibTeX
@article{Schiele2025,
  author = {Schiele, Francois and Farnier, Michel and Borsik, Bénédicte},
  title = {Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France},
  journal = {Archives of Cardiovascular Diseases},
  year = {2025},
  doi = {10.1016/j.acvd.2025.08.008}
}
Kostenlos starten →